Edition:
United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

21.40USD
9:00pm BST
Change (% chg)

$-1.03 (-4.59%)
Prev Close
$22.43
Open
$22.67
Day's High
$22.74
Day's Low
$21.13
Volume
221,149
Avg. Vol
181,174
52-wk High
$36.12
52-wk Low
$16.97

Rozenman, Mary 

Ms. Mary M. Rozenman is Senior Vice President - Strategy and Corporate Development of the Company, Dr. Rozenman has served as our Senior Vice President, Corporate & Strategy Development since February 2016. From February 2015 to February 2016, Dr. Rozenman served as our Senior Vice President, Corporate and Commercial Development. From February 2013 to January 2015, Dr. Rozenman was Vice President at Longitude Capital Management Co., LLC, a venture investment company, where she focused on biotechnology investments in therapeutics and diagnostics. From February 2008 to January 2013, Dr. Rozenman was at McKinsey & Company, a management-consulting company, where she most recently served as Associate Principal in the Healthcare and Corporate Finance practices. Dr. Rozenman previously served as an observer on the boards of directors of Allergen Research Corporation (now Aimmune Therapeutics, Inc.), Esperion Therapeutics, Inc., a biopharmaceutical company, and CardioDx, Inc., a molecular diagnostics company. Dr. Rozenman received a B.A. in Biochemistry and Russian Literature from Columbia University and a Ph.D. in Organic Chemistry and Chemical Biology from Harvard University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --